Biomarker testing remains a cornerstone of precision oncology, particularly for non–small cell lung cancer, yet obstacles ...

Terminology shifts to “decompensated heart failure,” introducing an initial–stabilization–pre/postdischarge framework and ...

Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk ...

Reference countries have limited room to simply raise their own drug budgets to absorb the pressure, the lead study author ...

PrecivityAD2 is cleared for adults ≥40 with cognitive impairment symptoms and is intended to complement, not replace, standard diagnostic evaluation incorporating history, exam, cognitive testing, ...

Increased care fragmentation among chronically ill, commercially insured patients is associated with higher costs and lower quality of care. ABSTRACTObjectives: To assess the relationship between care ...

Yet H. Khor, MD, PhD, explains why a 20% emphysema threshold on CT imaging may better define combined PF and emphysema in ...

UK Biobank data linked 7-day wrist light sensing to CMR 3.1 years later, contrasting >3 lux nighttime exposure with none.

Francesca Puggioni, MD, explains how real-world registry data, like the EU-ADVANTAGE study, informs regulatory decisions on ...

Fibrotic interstitial lung diseases, like idiopathic pulmonary fibrosis (IPF), commonly overlap with lung cancer—a key ...

Tozorakimab targets IL-33 upstream of TH2 pathways, cutting COPD exacerbations up to 34% in former smokers, Frank Sciurba, MD ...

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests escalating treatment in patients with chronic ...